CXCR4 plays a crucial role in the inflammatory disease process, providing an attractive means for drug targeting. A series of novel amide-sulfamide derivatives were designed, synthesized and comprehensively evaluated. This new scaffold exhibited much more potent CXCR4 inhibitory activity, with more than 70% of the compounds showed notably better binding affinity than the reference drug AMD3100 in the binding assay. Additionally, in the Matrigel invasion assay, most of our compounds significantly blocked the tumor cell invasion, demonstrating superior efficacy compared to AMD3100. Furthermore, compound IIj blocked mice ear inflammation by 75% and attenuated ear edema and damage substantially in an in vivo model of inflammation. Western blot analyses revealed that CXCR4 modulator IIj significantly blocked CXCR4/CXCL12-mediated phosphorylation of Akt. Moreover, compound IIj had no observable cytotoxicity and displayed a favourable plasma stability in our preliminary pharmacokinetic study. The preliminary structureactivity relationships were also summarized. In short, this novel amide-sulfamide scaffold exhibited potent CXCR4 inhibitory activity both in vitro and in vivo. These results also confirmed that developing modulators targeting CXCR4 provides an exciting avenue for treatment of inflammation.
mobilizer by dissociating CXCR4 from its ligand CXCL12, has been FDA-approved for the use in patients with multiple myeloma in order to mobilize and harvest stem cells [14, 15] .
Our lab has been developing partial CXCR4 modulators without cell mobilizing capability, which can be safe and effective in long term use [16, 17] . We designed and synthesized a series of novel and potent CXCR4 modulators (Class I shown in Fig. 1 ) [18, 19] . Among the promising candidates, compound 2 exhibits very low toxicity and excellent activity both in vitro and in vivo, and has been under Phase II clinical trials.
Taking the symmetrical bis-secondary amines (Class I) as lead structures, here we attempted to design and synthesize a novel series of anti-CXCR4 compounds. Based on the principle of bioisosteres, one imine bound (−NH−) in the side chain was substituted with an amide group (−CONH−). In addition, our previous work found that a sulfamide scaffold (−SO 2 NH −) is also an effective pharmacophore for CXCR4 inhibitory activity [20] . Therefore, the imine bound in the other side chain was then substituted with the sulfamide group, giving rise to the novel amide-sulfamide compounds. Preliminary docking study and bilological evaluation had proved this amide-sulfamide structure successfully maintained potent CXCR4 inhibitory activity [21] . Herein, the amide side chain was comprehensively modified and optimized. Nearly forty compounds were prepared and afforded a systematic biological analysis. The preliminary structure-activity relationship (SAR) was also summarized.
Results and discussion

Chemistry
The synthetic route chosen to synthesize the targeted compounds was outlined in Scheme 1. The target compounds were prepared from 4-(Boc-aminomethyl)benzylamine (3) . 
Primary binding affinity screening
All of the prepared compounds were first screened with a binding affinity assay as described in our previous publications [19, 20, 22] . This is a competitive binding assay between a potent CXCR4 peptidic inhibitor, biotinylated TN14003, and the target compounds Ia-r and IIa-r at concentrations of 1, 10, 100, and 1000 nM, for binding to the CXCR4 receptors. The effective concentration (EC) is defined as the lowest concentration at which a significant reduction in the rhodamine fluorescent color is observed as compared to control (Fig. 2 , without CXCR4 modulators). Thus, this initial screening is a semi-quantitative, primary screening of the level of activity, which is different from IC 50 .
When the two -NH-groups were substituted with -CONH-and -SO 2 NH-, respectively, the obtained amide-sulfamide parent structure successfully maintained significant CXCR4 binding affinity and showed even greater activity. Surprisingly, among the 34 synthesized compounds, only three compounds (If, IIa and IIq) displayed weaker binding affinity compared to the reference drug AMD3100. More than 70% of the compounds showed significant better binding effects (Table 1 and Fig. 2 ). Compounds Ia, Ib, Ie, Iii and IIj exhibited 1000-fold stronger potency than AMD3100, with an EC of only 1 nM. Generally, most of the derivatives substituted at the 2'-position of the benzamide group showed more potent activity. Incorporating a methyl group to the benzene sulfonamide side chain significantly enhanced the binding affinity. Further modification of the benzenesulfonamide group was needed to summarize and explain the the structure-activity relationships (SARs).
Matrigel invasion assay
Activation of CXCR4 through its ligand CXCL12 mediates migration and invasion. Thus, we used the Matrigel invasion assay to probe whether the selected compounds from our primary binding affinity assay can block CXCR4/CXCR12 mediated chemotaxis and invasion [20, 22] . The target compounds (100 nM) and cells were added to in the upper chamber of a vessel and CXCL12 was added in the lower chamber as a chemoattractant in serum-free medium. The binding of CXCR4 in cell surface with the selected compounds would block CXCL12 chemotaxis to the cells. Therefore, the MDA-MB-231 human breast cancer cells in the top chamber treated with the compounds would be inhibited to migrate from the top chamber through the Matrigel-coated filter pores to the bottom of the filter. The inhibition of cell invasion with each tested compound was calculated by comparing to the cell invasion without treatment. The results of Matrigel invasion were summarized in Fig. 3 and Fig. 4 . 24 compounds showing greater binding affinity than AMD3100 were selected for the Matrigel invasion assay. Most of the corresponding compounds displayed exceptional inhibition of CXCR4, except Id, In and IIb, with less than 50% inhibition. Compounds Io, IIg, IIi, IIo, IIp and IIr showed favorable blocking effect comparable to AMD3100 (55%), while Ia, Ii, Ij, Ik, Ip, Iq, Ir, IIj, IIm and IIn performed quite well in the Matrigel assay with more than 60% inhibition. Compounds Ib, Ie, IIe, IIf and IIk exhibited the most potent anti-invasion effect, preventing more than 90% cells from invading through the Matrigel gel. These invasion results give eloquent proof that the designed amide-sulfamide scaffold is a novel structure to block CXCR4 function.
In vivo suppression against xylene-induced ear edema
To evaluate the in vivo anti-inflammatory activity of the amide-sulfamide compounds, we performed a xylene-induced ear edema experiment [23] . This xylene-induced ear edema model is widely used in the evaluation of inflammatory activity. The application of xylene induces neurogenous edema, which is partially associated with substance P. In the periphery, release of substance P from sensory neurons leads to vasodilatation and plasma extravasations, which causes ear swelling in mice [24] .
Compounds achieving greater than 65% inhibition in the Matrigel assay were evaluated in the ear edema test. Although AMD3100 is the best investigated small molecule CXCR4 Most of the selected compounds displayed moderate to significant anti-inflammatory activity. Interestingly, compounds Ib, Ie, Ik, Ip and IIe demonstrated excellent anti-CXCR4 activity in the Matrigel invasion assay, but were ineffective in suppressing the mice ear inflammation ( Fig. 5 ). Compounds IIf and IIk also exhibited weak activity (28% and 26% inhibition). Substances Ij and Ir had moderate anti-inflammatory effect with ~40% inhibition. Meanwhile, compounds Iq, IIm and IIn suppressed inflammation by 53%, 57% and 50%, respectively. Surprisingly, compounds Ia and IIj showed excellent suppressive activity with 62% and 75% inhibition, respectively.
Histological analysis was then performed to further investigate the significant antiinflammatory activity of compound IIj. As shown in Fig. 6 , a histological assay of compound IIj showed remarkable attenuation of ear inflammation and damage with decreases in ear thickness, edema volume, and the number of inflammatory cells (C1-2). These results confirm that the amide-sulfamide compound IIj targeting CXCR4 can inhibit inflammation as anticipated. In addition, developing anti-CXCR4 agents for inflammation provides an exciting avenue to target different pathways from COX.
Evaluation of anti-CXCR4 activity of compound IIj at the molecular level
Phosphoinositide 3-kinase (PI3K) activates Akt, a serine threonine kinase which plays a key role in tumor cell survival and possibly proliferation. PI3K/Akt pathways are independently involved in the proliferative signal mediated by CXCL12 [25] . Our previous results demonstrated that CXCR4/CXCL12 induced Akt phosphorylation, which resulted in tumor angiogenesis and progression of tumors by increasing expression of vascular endothelial growth factor (VEGF) through the activation of the PI3K/Akt pathway [26] . The activity of IIj in blocking the PI3K/Akt pathway was investigated by Western blot analysis. As shown in Fig. 7 , CXCR4 modulator IIj blocked the CXCR4/CXCL12-mediated phosphorylation of Akt in a dose-dependent manner, and significantly inhibited phosphorylation at concentrations of 10 and 100 nM.
Preliminary cytotoxicity evaluation of compound IIj
In addition to their therapeutic effects, cytotoxic agents have the potential of causing serious destruction to healthy and normal cells. To preliminarily evaluate the safety of compound IIj, its cytotoxicity was evaluated on two representative human breast cancer cell lines, MDA-MB-231(CXCR4-positive) and MCF-10A (CXCR4-negative) by a cell viability (MTT) assay. Of note, blocking CXCR4 does not impact adherent cell proliferation [27] . Compound IIj displayed potent CXCR4 binding affinity at only 1 nM, however, it did not inhibit the proliferation of MDA-MB-231and MCF-10A cells even at concentrations as high as 10 µM (Fig. 8 ), a 1000-fold increase to the working concentrations. Generally, IIj had no observable cytotoxicity.
Preliminary pharmacokinetic study of compound IIj
The plasma stability of a drug has a significant influence on the concentration of drug available in circulation. To determine the preliminary pharmacokinetics of these amidesulfamide compounds, the concentration and stability of compound IIj in plasma were evaluated in a mouse model. The peak area of IIj in plasma was detected by high-performance liquid chromatography (HPLC) at three time points: 5, 20 and 50 minutes. Generally, compound IIj demonstrated a satisfying plasma stability. When normalizing the concentration of compound IIj to the peak area at 5 minutes (100%), the concentration remained 65% and 45% at 20 and 50 minutes, respectively ( Fig. 9 ). The approximate halflife (t 1/2 ) was calculated to be ~40 minutes. However, the basal metabolic rate per gram of body weight (the mass-specific rate) is seven times greater in mice than in humans [28] . Therefore, we inferred that t 1/2 of IIj in human would be reasonable. Compared to a previously reported candidate belonging to Class I [19] , which was nearly undetectable by HPLC within 1 hour, IIj exhibited favorable plasma stability. The amide-sulfamide structure is not only effective both in vitro and in vivo, but is also a metabolically tolerated pharmacophore.
Discussion of Structure-activity relationships (SARs) discussion
Based on the results of binding affinity screening, Matrigel invasion test and in vivo antiinflammatory evaluation, the preliminary SARs were then characterized ( Fig. 10 ).
In terms of binding affinity, the benzamide side chain showed favorable tolerance. The influence of electron-withdrawing and electron-donating groups on the binding activity did not demonstrate a notable difference; both could maintain or improve the binding affinity. When the 2'-position of the benzamide side chain was substituted, most of the derivatives exhibited better affinity, which was basically stronger than the 3' or 4'-position substituted compounds. A direct comparison between the 3' and 4'-position substituted derivatives showed no obvious difference in binding affinity. Moreover, when an electron-donating substituent, such as a methyl group, was introduced to the 4'-position of the benzene sulfonamide side chain, binding affinity increased significantly. Further modification on the benzene sulfonamide structure is needed.
In terms of the Matrigel invasion test, the benzamide scaffold was still tolerated. Both electron-withdrawing and electron-donating groups enhanced the inhibitory potency. When the 2'-position was substituted with methyl, methoxyl or chlorine groups, these corresponding compounds displayed the most potent activity, better than 3' or 4'-position modified compounds. In contrast, when substituted with fluorine, the 3' and 4'-position substituted compounds demonstrated a greater effect.
In the in vivo anti-inflammatory evaluation, when the 4'-position of benzamide side chain was substituted, the melting point increased significantly, especially with strong electronwithdrawing groups. These changes decreased the solubility of the target compounds, and may also impact the bioavailability. Although compound IIj (4'-position substituted with fluorine) showed the strongest anti-inflammatory activity, its solubility was not favourable. Taking IIj as the lead compound, introducing groups containing nitrogen atoms to the benzene sulfonamide structure will be an advisable strategy in the future optimization. The obtained compounds can be converted into salts to address the solubility issues.
All in all, compared to the bis-secondary amine lead structure, this novel amide-sulfamide scaffold successfully maintained the potent CXCR4 blocking effect, and showed even stronger activity both in vitro and in vivo. Based on the summarized SARs, further modification and optimization will be performed, especially to the benzene sulfonamide side chain.
Conclusion
Taking the symmetrical bis-secondary amines (Class I) as lead structures, a series of novel amide-sulfamide derivatives were designed, synthesized and comprehensively evaluated. This novel amide-sulfamide scaffold not only maintained significant CXCR4 modulating effect, but also exhibited more potent anti-CXCR4 activity. In the in vitro assays, more than 70% of compounds showed notably better binding affinity than the reference drug AMD3100. Compounds Ia, Ib, Ie, Iii and IIj exhibited 1000-fold stronger potency than AMD3100, with an EC of only 1 nM. In the Matrigel invasion assay, most of the compounds significantly blocked tumor cell invasion, demonstrating superior inhibition compared to AMD3100. For the in vivo evaluation, compounds Ia and IIj showed excellent mice ear inflammation suppressive activity (62% and 75%, respectively). Histological analysis proved that compound IIj attenuated ear edema and damage substantially, with ear thickness, edema volume, and the number of inflammatory cells all decreasing by a wide margin. Western blot analyses revealed that CXCR4 modulator IIj blocked the CXCR4/CXCL12-mediated phosphorylation of Akt in a dose-dependent manner. Compound IIj also significantly attenuated the amount of TNF-α by 59% in bacterial-infected J774A.1 macrophages. In the preliminary pharmacokinetic study, compound IIj also displayed a favourable plasma stability. In the cytotoxicity screening, IIj did not inhibit the proliferation of MDA-MB-231and MCF-10A cells even at 10 µM, and showed no observable cytotoxicity.
Based on the results of binding affinity screening, Matrigel invasion test, in vivo antiinflammatory evaluation and preliminary pharmacokinetic study, the preliminary SARs were summarized. Future directions for this work will include further optimization and modification of the benzene sulfonamide scaffold, especially the introduction of hydrophilic structures or groups containing nitrogen atom(s) to improve the solubility and bioavailability.
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Experimental section
General procedure for synthesis of intermediate 4-A solution of 4-(Bocaminomethyl)benzylamine
2-Methoxy-N-(4-(phenylsulfonamidomethyl)benzyl)benzamide (Ie
3-Fluoro-N-(4-(phenylsulfonamidomethyl)benzyl)benzamide (Ii
Primary binding affinity screening
For binding affinity assay, 2 × 10 4 MDA-MB-231 cells in 300 µL of cell culture medium were seeded in an 8-well slide chamber 2 days before the experiments were conducted. Various concentrations of different compounds (1, 10, 100, or 1000 nM) were added to the separate wells and incubated for 10 minutes at room temperature, and then the cells were fixed in 4% ice-cold paraformaldehyde. The cells were rehydrated in phosphate-buffered saline (PBS). The slides were subsequently incubated for 30 minutes at room temperature with 0.05 µg/mL biotinylated TN14003, washed three times with PBS, and incubated in streptavidin-rhodamine (1:150 dilution; Jackson ImmunoResearch Laboratories, West Grove, PA) for 30 minutes at room temperature. Finally, the slides were washed with PBS and mounted in an anti-fade mounting solution (Molecular Probes, Eugene, OR), and the samples were analyzed on a Nikon Eclipse E800 microscope [19, 20, 22] . 
Matrigel invasion assay
Xylene-induced ear inflammation suppression test
Five mice per group were used to determine the effect of the CXCR4 modulators. The inner and outer surfaces of the right ear of each mouse were treated with a total 30 µL of xylene for the induction of ear edema, whereas the left ear was treated with 30 µL of saline, which was used as a non-inflammation control. The selected compounds were dissolved in 10% DMSO and 90% of 45% (2-hydroxypropyl)-β-cyclodextrin (CD) in PBS. 30 minutes after the application of xylene, 14 selected compounds were administered intraperitoneally (i.p.) at 10 mg/kg. Control animals received corresponding i.p. injections of the vehicle. The animals were sacrificed 2 hours later, and two ear plugs (7 mm in diameter) were removed from both the treated ear and the untreated ears. Weights of treated and untreated ear plugs were measured. The difference in weight of the two ear plugs was taken as a measure of edematous response. The inflammation-suppression percentage was calculated by comparing the drug-treated group to the control group [23] .
Western blot analysis
Forty micrograms of protein were separated by SDS-PAGE and transferred to a PVDF membrane (Bio-Rad, Hercules, CA, USA). The membrane was blocked for 30 min in a blocking solution (5 % milk in Trisbuffered saline containing 0.1% Tween-20) and incubated overnight at 4°C using monoclonal rabbit anti-phospho-Akt (Ser473) antibody (Cat No., 9271)/monoclonal rabbit anti-Akt (pan) antibody (cat No., 4691) or monoclonal rabbit anti- Representative immunofluorescence images of competition-binding affinity assay of three selected compounds compared to AMD3100. CXCR4 receptors on the cell surface are shown in red fluorescent color in this binding affinity assay using biotinylated TN14003 that binds to CXCR4. When our test compounds are preincubated with the cells and block the binding of biotinylated TN14003, the red fluorescent color gets reduced. The effective concentration (EC) of AMD3100 was 1000 nM, while compounds Ie, IIj and Iq showed much better EC of only 1, 1 and 10 nM, respectively. Summary of Matrigel invasion assay results induced by CXCR4/CXCL12-mediated interaction using MDA-MB-231 cells in the presence of CXCR4 modulators (all compounds, P < 0.05). CXCL12α was added to the bottom chamber, and the compounds were added to the top chamber. After incubating for 22 hours, the invading cells were fixed in methanol and stained with hematoxylin and eosin. The percent of invasion was determined by counting the stained cells. 0% inhibition was determined with CXCL12α added to the bottom chamber, but without any CXCR4 inhibitor. 100% was defined by counting the stained cells without adding CXCL12α nor compound. Compounds achieving greater than 65% inhibition (over blue line) were evaluated in the ear edema test. 
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Author Manuscript In vivo anti-inflammatory activity of 14 selected compounds (n=5, * P < 0.05). The right ear of each mouse was treated with a 30 µL of xylene. The selected compounds were administered intraperitoneally (i.p.) at 10 mg/kg, 30 minutes later. Two hours later, one each ear plug was removed from both ears and weighed to calculate the inflammation-suppression percentage. Table 1 Preliminary effective concentration (EC) of anti-CXCR4 compounds. 
